Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ketek Act I: FDA Updates Label, Touts Process On Eve Of Hearing

This article was originally published in The Pink Sheet Daily

Executive Summary

Agency says it has “learned” from controversy surrounding the antibiotic, but FDA will likely still face congressional grilling about its actions.
Advertisement

Related Content

Antibiotics Legislation Could Boost Confidence Of Sponsors And FDA Alike
House Panel May Subpoena FDA Investigators To Address Ketek Safety Study
House Panel May Subpoena FDA Investigators To Address Ketek Safety Study
Advanced Life Sciences’ Once-Daily Cethromycin Non-Inferior To Biaxin In First Pivotal Trial
Advanced Life Sciences’ Once-Daily Cethromycin Non-Inferior To Biaxin In First Pivotal Trial
FDA Safety Decisions On Ketek To Get Formal Review By House Committee
FDA Safety Decisions On Ketek To Get Formal Review By House Committee
Pilot Program Will Review First-Year Safety Data for Several NMEs
Pilot Program Will Review First-Year Safety Data for Several NMEs
Ketek Risk Cannot Be Distinguished From Class, FDA Says

Topics

Advertisement
UsernamePublicRestriction

Register

PS065617

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel